Persistent smokers after myocardial infarction: a group that requires special attention

Loukianos S Rallidis1, Eftichia S Hamodraka, Valerios O Foulidis

  • 1Department of Cardiology, General Hospital of Nikea, Piraeus, Greece. rallidis@ath.forthnet.gr

Insights

Patients with coronary heart disease who continue to smoke after myocardial infarction (MI) show poorer health behaviors. These persistent smokers require targeted interventions to improve medication compliance and encourage smoking cessation.

Area of Science:

  • Cardiology
  • Public Health
  • Behavioral Science

Background:

  • Smoking remains prevalent in patients with coronary heart disease.
  • Continued smoking post-myocardial infarction (MI) poses significant cardiovascular risks.
  • Understanding lifestyle and medication adherence in these patients is crucial.

Purpose of the Study:

  • To assess medication compliance and attitudes towards lifestyle changes in post-MI smokers.
  • To identify risk factors associated with continued smoking after myocardial infarction.
  • To evaluate the health status of persistent smokers compared to non-smokers.

Main Methods:

  • 1011 patients with history of MI (>6 months, <75 years) were recruited.
  • Data collected via interviews, lipid measurements, and HbA1c for diabetics.
  • Comparison between persistent smokers and non-smokers.

Main Results:

  • Persistent smokers had lower HDL cholesterol (p=0.001).
  • Diabetic smokers exhibited poorer glycemic control (HbA1c, p=0.001).
  • Fewer smokers used hypolipidemic drugs (p=0.005) and exercised regularly (p=0.008).

Conclusions:

  • Post-MI smokers display negative health attitudes and lower medication compliance.
  • Persistent smokers represent a high-risk subgroup needing specialized smoking cessation support.
  • Interventions should focus on encouraging smoking cessation and improving adherence to treatment.
Abstract

Related Concept Videos

Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...